Laura A. Williams, director of patient relations at Ardelyx Inc., sold 10,739 common shares on Aug. 21, 2026, generating proceeds of $41,419 at prices between $3.648 and $3.984 per share.
The transaction was executed automatically to cover tax withholdings tied to the vesting of restricted stock units, according to regulatory filings. Williams retained 367,456 Ardelyx shares following the sale.
The disposal occurred as Ardelyx’s stock traded near its 52-week low of $3.73, down 43% over the prior six months. Revenue rose 31% in the second quarter to a record $118 million, but the company withdrew its annual revenue guidance for XPHOZAH and revised projections for IBSRELA, contributing to investor uncertainty.
Options activity surged, with put contracts totaling 10,676, signaling heightened bearish sentiment. Ardelyx’s shares remain under pressure despite the revenue increase, with InvestingPro analysis flagging the stock as undervalued while analysts maintained a Strong Buy consensus.
